side effects of glp 1 tirzepatide vs. Semaglutide: What You Should Know GLP-1 Agonists: Using Semaglutide, Tirzepatide,

This research and knowledge related to the mode of action have been successfully translated into clinical pharmacology and have been and are a game-changer in T2D and, to some extent, in obesity

Beyond 24 Weeks The Phase 3 trials are ongoing and running longer durations

Oral Wegovy (semaglutide) has demonstrated a 15% weight-loss average in clinical trials, while Foundayo (orforglipron) has helped people lose approximately 12% to 14% of their starting weight

Weight appeared to plateau around weeks 44 to 48 for most participants, suggesting the body reaches a new equilibrium point rather than continuing to lose indefinitely

So, its essential we transition to a diet based on whole foods to maximise the results of semaglutide

10.1038/ajg.2010.363 56